ODI Pharma AB (publ) (NGM:ODI)

ODI Pharma AB Balance Sheet

Financials in millions SEK. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	2.89	1.48	2.64	6.49	7.36	14.62
Cash & Short-Term Investments	2.89	1.48	2.64	6.49	7.36	14.62
Cash Growth	-42.14%	-43.87%	-59.28%	-11.76%	-49.69%	-28.71%
Accounts Receivable	3.26	0.12	8.07	0.13	0.11	-
Other Receivables	1.05	3.78	0.91	0.68	0.99	0.93
Receivables	4.31	3.89	8.98	0.81	1.09	0.93
Inventory	-	-	-	0.81	1.43	1.05
Prepaid Expenses	0.19	0.38	0.59	0.06	-	-
Other Current Assets	-	-	-	0	0.6	0.26
Total Current Assets	7.39	5.75	12.22	8.18	10.48	16.87
Property, Plant & Equipment	0	0	0.01	0.01	0.01	0.01
Other Long-Term Assets	-	-	0	-	-	-
Total Assets	7.39	5.76	12.23	8.19	10.5	16.88
Accounts Payable	3.99	0.75	5	0.71	0.67	0.15
Accrued Expenses	0.32	1.26	1.16	0.35	-	-
Current Income Taxes Payable	-	0	0.09	0	-	-
Current Unearned Revenue	-	-	-	-	0.55	0.4
Other Current Liabilities	2.79	2.94	3.98	4.54	0.01	0.04
Total Current Liabilities	7.1	4.94	10.23	5.61	1.24	0.58
Total Liabilities	7.1	4.94	10.23	5.61	1.24	0.58
Common Stock	0.73	0.73	0.61	0.61	0.61	0.61
Additional Paid-In Capital	27.08	25.96	21.84	21.84	21.84	21.84
Comprehensive Income & Other	-27.52	-25.88	-20.45	-19.88	-13.19	-6.15
Shareholders' Equity	0.29	0.81	2	2.57	9.26	16.3
Total Liabilities & Equity	7.39	5.76	12.23	8.19	10.5	16.88
Net Cash (Debt)	2.89	1.48	2.64	6.49	7.36	14.62
Net Cash Growth	-42.14%	-43.87%	-59.28%	-11.76%	-49.69%	-28.71%
Net Cash Per Share	0.15	0.08	0.17	0.42	0.49	0.95
Filing Date Shares Outstanding	18.33	18.35	15.22	15.22	15.22	15.22
Total Common Shares Outstanding	18.33	18.35	15.22	15.22	15.22	15.22
Working Capital	0.29	0.81	1.99	2.56	9.25	16.29
Book Value Per Share	0.02	0.04	0.13	0.17	0.61	1.07
Tangible Book Value	0.29	0.81	2	2.57	9.26	16.3
Tangible Book Value Per Share	0.02	0.04	0.13	0.17	0.61	1.07
Machinery	-	-	0.04	0.04	0.04	0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.